

CSP #2028 (EPIC<sup>3</sup>) Biospecimens and Surveys Collected (Number of Participants per Study Visit)

Updated: 09/04/2024

<b>CLC Cohort</b>																
	Pre-Day 0	Day 0	Day 3	Day 7	Day 14	Day 21	Day 28	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24	
<b>PBMC</b>		<b>88</b>						<b>38</b>	<b>43</b>	<b>33</b>	<b>51</b>	<b>21</b>	<b>43</b>	<b>18</b>	<b>42</b>	
SARS-CoV-2 Positive		12						4	6	1	7	2	5	2	4	
SARS-CoV-2 Negative		76						34	37	32	44	19	38	16	38	
<b>Plasma (EDTA)</b>		<b>105</b>						<b>49</b>	<b>53</b>	<b>37</b>	<b>56</b>	<b>24</b>	<b>52</b>	<b>20</b>	<b>47</b>	
SARS-CoV-2 Positive		12						5	7	1	8	2	8	2	5	
SARS-CoV-2 Negative		93						44	46	36	48	22	44	18	42	
<b>Plasma (Sodium Citrate)</b>		<b>54</b>						<b>21</b>	<b>13</b>	<b>9</b>	<b>29</b>	<b>13</b>	<b>51</b>	<b>19</b>	<b>48</b>	
SARS-CoV-2 Positive		5						2	1		6		8	2	5	
SARS-CoV-2 Negative		49						19	12	9	23	13	43	17	43	
<b>Plasma (Other)</b>		<b>15</b>						<b>5</b>	<b>19</b>	<b>19</b>	<b>27</b>	<b>11</b>	<b>3</b>			
SARS-CoV-2 Positive		6						1	4		2	2				
SARS-CoV-2 Negative		9						4	15	19	25	9	3			
<b>Serum (venous)</b>		<b>106</b>						<b>49</b>	<b>56</b>	<b>39</b>	<b>54</b>	<b>25</b>	<b>55</b>	<b>24</b>	<b>50</b>	
SARS-CoV-2 Positive		12						5	8	2	7	2	8	2	6	
SARS-CoV-2 Negative		94						44	48	37	47	23	47	22	44	
<b>Serum (capillary, extremely limited volumes)</b>							<b>2</b>	<b>2</b>	<b>3</b>	<b>1</b>	<b>4</b>		<b>3</b>	<b>2</b>	<b>2</b>	
SARS-CoV-2 Positive																
SARS-CoV-2 Negative							2	2	3	1	4		3	2	2	
<b>Buffy Coat</b>		<b>59</b>						<b>34</b>	<b>50</b>	<b>37</b>	<b>57</b>	<b>23</b>	<b>54</b>	<b>19</b>	<b>48</b>	
SARS-CoV-2 Positive		7						4	8	1	8	2	8	2	5	
SARS-CoV-2 Negative		52						30	42	36	49	21	46	17	43	

CLC Cohort	Pre-Day 0	Day 0	Day 3	Day 7	Day 14	Day 21	Day 28	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
<b>PAXgene Blood RNA Tube (intracellular RNA stabilized)</b>		<b>104</b>						<b>45</b>	<b>53</b>	<b>33</b>	<b>54</b>	<b>24</b>	<b>54</b>	<b>18</b>	<b>45</b>
SARS-CoV-2 Positive		12						5	8	1	8	2	8	2	5
SARS-CoV-2 Negative		92						40	45	32	46	22	46	16	40
<b>NP Swab</b>	<b>3</b>	<b>12</b>						<b>13</b>	<b>14</b>	<b>13</b>	<b>13</b>	<b>15</b>	<b>11</b>	<b>6</b>	<b>1</b>
SARS-CoV-2 Positive									3	1	1	2	1	1	1
SARS-CoV-2 Negative	3	12						13	11	12	12	13	10	5	
<b>OP Swab</b>		<b>3</b>													
SARS-CoV-2 Positive															
SARS-CoV-2 Negative		3													
<b>Saliva (no preservative)</b>								<b>2</b>	<b>9</b>	<b>8</b>	<b>26</b>		<b>22</b>		<b>26</b>
SARS-CoV-2 Positive								1	3		5		4		3
SARS-CoV-2 Negative								1	6	8	21		18		23
<b>Saliva (stabilizing preservative)</b>		<b>4</b>			<b>1</b>		<b>2</b>		<b>4</b>	<b>1</b>	<b>5</b>	<b>1</b>	<b>3</b>	<b>2</b>	<b>2</b>
SARS-CoV-2 Positive		1													
SARS-CoV-2 Negative		3			1		2		4	1	5	1	3	2	2
<b>FluPRO Questionnaire</b>	<b>1</b>	<b>144</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>5</b>	<b>105</b>	<b>85</b>	<b>66</b>	<b>95</b>	<b>44</b>	<b>94</b>	<b>37</b>	<b>80</b>
SARS-CoV-2 Positive		16						10	9	3	14	4	9	3	8
SARS-CoV-2 Negative	1	128	2	1	1	2	5	95	76	63	81	40	85	34	72
<b>Long Term Symptoms Questionnaire</b>	<b>1</b>	<b>3</b>	<b>1</b>		<b>1</b>	<b>2</b>	<b>5</b>	<b>105</b>	<b>85</b>	<b>65</b>	<b>94</b>	<b>44</b>	<b>93</b>	<b>37</b>	<b>80</b>
SARS-CoV-2 Positive		1						10	9	3	14	4	9	3	8
SARS-CoV-2 Negative	1	2	1		1	2	5	95	76	62	80	40	84	34	72

CLC Cohort	Pre-Day 0	Day 0	Day 3	Day 7	Day 14	Day 21	Day 28	Month 3	Month 6	Month 9	Month 12	Month 15	Month 18	Month 21	Month 24
<b>Vaccines Questionnaire</b>	<b>1</b>	<b>3</b>	<b>1</b>		<b>1</b>	<b>2</b>	<b>5</b>	<b>105</b>	<b>85</b>	<b>65</b>	<b>94</b>	<b>44</b>	<b>93</b>	<b>37</b>	<b>80</b>
SARS-CoV-2 Positive		1						10	9	3	14	4	9	3	8
SARS-CoV-2 Negative	1	2	1		1	2	5	95	76	62	80	40	84	34	72
<b>MVP COVID-19 Questionnaire, Module 1</b>		<b>137</b>					<b>1</b>	<b>11</b>		<b>4</b>	<b>1</b>	<b>3</b>			
SARS-CoV-2 Positive		15						3							
SARS-CoV-2 Negative		122					1	8		4	1	3			
<b>MVP COVID-19 Questionnaire, Module 2</b>		<b>135</b>					<b>1</b>	<b>11</b>		<b>4</b>	<b>1</b>	<b>3</b>	<b>1</b>		
SARS-CoV-2 Positive		15						3							
SARS-CoV-2 Negative		120					1	8		4	1	3	1		
<b>MVP COVID-19 Questionnaire, Module 3</b>		<b>132</b>					<b>1</b>	<b>12</b>	<b>1</b>	<b>4</b>	<b>1</b>	<b>3</b>	<b>1</b>		
SARS-CoV-2 Positive		15						3							
SARS-CoV-2 Negative		117					1	9	1	4	1	3	1		
<b>MVP COVID-19 Questionnaire, Module 4</b>		<b>132</b>			<b>1</b>			<b>12</b>		<b>3</b>	<b>1</b>	<b>3</b>			
SARS-CoV-2 Positive		15						3							
SARS-CoV-2 Negative		117			1			9		3	1	3			
<b>MVP COVID-19 Questionnaire, Module 5</b>		<b>132</b>					<b>1</b>	<b>10</b>		<b>3</b>	<b>1</b>	<b>3</b>	<b>1</b>		
SARS-CoV-2 Positive		15						3							
SARS-CoV-2 Negative		117					1	7		3	1	3	1		